Kalray Unveils Its K200-LP Latest Acceleration Card for Data Centers
16.6.2021 08:30:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider in the new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, today unveils its new K200-LP™ acceleration card. K200-LP™ is a new member of Kalray’s fully programmable multi-purpose acceleration card family, based on its unique MPPA® processor, and offering an unprecedented level of performance and targeting the booming NVMe based storage market as its first implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615006166/en/
Kalray's K200-LP Acceleration Card (Photo: Kalray)
The explosion of data, driven by demanding services and applications using AI and data analytics, is putting a lot of pressure on Cloud and Edge Data Center’s networking and storage to feed the demanding compute intensive resources. The primary needs are to reduce latency, enhance bandwidth and IOPs1 performance as well as offloading host CPUs, at best cost.
Data centers are looking for solutions that enable high performance, low power, cost effectiveness and openness to scale and match demand on data availability. The K200-LP™ acceleration card is Kalray’s solution to address these exacting demands for their data center customers.
Eric Baissus, President and CEO of Kalray, said: “We are proud to unveil our new K200-LP™ acceleration card, based on our MPPA® processor. This family of Ethernet/PCIe acceleration cards are natively capable of managing multiple workloads with no bottleneck to enable smarter, more efficient, and energy-wise applications on Cloud and Edge data centers. To address the new generation of storage array solutions for Cloud and Edge, K200-LP™ is a game changer solution in terms of performance per Watt and per dollar.”
To improve and optimize overall IT infrastructures, the industry has moved increasingly towards disaggregated storage. Put simply, separating compute resources and storage resources.
1 IOPS is the numbers of Input/Output operations per second and is a performance measurement used to characterize computer storage devices.
Most advanced All-Flash-Array solutions today use multiple adapter cards around a x86 that runs storage services. Kalray manages to run all the critical functions of a disaggregated storage appliance on one single chip: the Kalray MPPA® processor. Advanced Data Processing Units (DPU) like MPPA® and associated acceleration cards can run, efficiently and on a cost-optimized manner versus traditional x86, new protocols such as NVMe and NVMe-over-Fabric to access and unleash the full capability of SSDs wherever they are located in the Data Center as if there were locally attached.
Whereas the industry has defined a new NVMe protocol to support the latest generation of ultra-fast storage devices, existing traditional technologies are not capable of exposing the full capability of NVMe-based SSDs. Kalray’s K200-LP™ smart storage card has been built from the ground-up to support those breaking through data protocols. Based on Kalray MPPA’s processor, K200-LP™ is also the perfect solution for storage array appliance makers and cloud service providers, to build their next generation of storage appliances in terms of performance per Watt per $.
Kalray’s K200-LP™ acceleration card is a low-profile, 2x 100GB ethernet, PCIe Gen4 card that can deliver more than 2 MIOPS and 12 GB/s per card (both RoCE and TCP) with a latency as low as 30 microseconds. K200-LP™ has been developed by Kalray and is manufactured by Taiwanese Wistron, one of the largest manufacturers of electronic cards and data center servers in the world.
Kalray’s K200-LP™ smart storage card and associated tools are available now.
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, leading provider in a new generation of processors specialized in Intelligent Data Processing from Cloud to Edge. Kalray MPPA® Intelligent Processors are able to capture and analyze on the fly massive data flows, and interact in real time with the outside world. These processors are capable of running demanding AI algorithms and simultaneously a wide set of different processing and control tasks such as intensive mathematical algorithms, signal processing, network or storage software stacks. Kalray’s Intelligent Processors can be deployed in fast-growing sectors from Cloud to Edge: modern data centers, 5G telecom networks, autonomous vehicles, healthcare equipment, industry 4.0, drones and robots… Kalray’s offering includes processors, acceleration cards and a software suite, for a broad spectrum of customers such as next generation data center equipment manufacturers and service providers, system integrators and consumer product manufacturers such as car makers. Founded in 2008 as a spin-off of CEA French lab, Kalray counts among its investors: Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance. Read more at: www.kalrayinc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615006166/en/
Contact information
INVESTORS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
+33 (0)4 76 18 90 71
ACTUS finance & communication
Jérôme FABREGUETTES-LEIB
kalray@actus.fr
+33 1 53 67 36 78
MEDIA
Loic HAMON
communication@kalrayinc.com
+33 (0)4 76 18 90 71
ACTUS finance & communication
Serena BONI
sboni@actus.fr
+33 (0)4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
